(The 3rd CIIE) Dialogue with Ye Tiancheng, General Manager of Edward Life Sciences Greater China: Participating in the CIIE is a new milestone in China
China News Service, Shanghai, November 8th, title: Dialogue with Ye Tiancheng, general manager of Edward Life Sciences Greater China: Participating in the CIIE is a new milestone in China
China News Agency reporter Miao Lu and Li Jiajia
As the "originator" enterprise in the field of heart valves, Edward Life Sciences made its debut at the China International Import Expo with dual booths. In an exclusive interview with a reporter from China News Agency, Ye Tiancheng, general manager of Edward Life Sciences Greater China, said: "For us, participate in the The Expo is a new milestone in Edward's deep cultivation in China."
Edward Life Sciences has set up two booths this time, one in the medical equipment and medicine and healthcare exhibition area, and the other in the new crown epidemic prevention area.
In these two areas, Edward Life Sciences concentrated on displaying innovative global leading products in four business areas, including Edward Life Sciences’ iconic product Sapien 3, the latest generation of balloon-expandable (ball-expandable) transcatheter The debut of the arterial valve replacement system also marks the official launch of the product in China.
Edward Life Sciences has been developing in China for nearly 20 years. "To bring the most innovative products to China, we need to invest the best team and resources to support Chinese clinical institutions to carry out local clinical trials and accumulate local clinical data. But we are very Pay attention to the Chinese market and believe that this investment is worthwhile.” Ye Tiancheng said, “The Chinese market is developing very fast, with double-digit growth every year.”
Although the introduction of innovative products into the Chinese market requires a lot of investment, Ye Tiancheng said: "Edward Life Sciences' market includes four major regions, namely the United States, the European Union, Japan, and Greater China. We attach great importance to the rapid growth of Greater China. At present, a lot of our investment is in introducing innovative products into the Chinese market."
"Our investment in the Chinese market is in all aspects, not only to open a new factory, new office or R&D center, but we also hope to share the many clinical experiences of products on the market in other countries with Chinese doctors and research scholars. , To cooperate with Chinese companies to understand China’s medical policy trends.” Ye Tiancheng said.
In Ye Tiancheng's eyes, the CIIE provides a stage for them to achieve these goals. "The CIIE provides us with a major opportunity, not only to showcase products, but also to point out the direction for us to further develop the Chinese market."
The current CIIE has not yet come to an end, but Ye Tiancheng has already calculated the plan for the next CIIE. “At this stage, we are already following up with the CIIE to discuss next year’s participation. An opportunity for organizations, industries, and the public to communicate and communicate. I think this is a very valuable gathering." (End)